{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:49:00Z","timestamp":1789505340969,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ekir.2022.02.023","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T12:58:43Z","timestamp":1646398723000},"page":"1084-1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With\u00a0Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2794-2263","authenticated-orcid":false,"given":"Rosalie A.","family":"Scholtes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel H.A.","family":"Muskiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel J.B.","family":"van Baar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Hesp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hammarstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Hallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.02.023_bib1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome","volume":"12","author":"van Bommel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.02.023_bib2","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.02.023_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.02.023_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.02.023_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.02.023_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation","volume":"17","author":"Marton","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.02.023_bib12","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2022.02.023_bib13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.HYP.29.6.1240","article-title":"Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local Prododuction of Angiotensin I","volume":"29","author":"de Lannoy","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.02.023_bib14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.108.123042","article-title":"Aliskiren accumulates in renin secretory granules and binds plasma prorenin","volume":"52","author":"Krop","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.02.023_bib15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.02.023_bib16","first-page":"F823","article-title":"Vasopressin effects on urea and H2O transport in inner medullary collecting duct subsegments","volume":"253","author":"Sands","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2022.02.023_bib17","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"10.1016\/j.ekir.2022.02.023_bib18","first-page":"779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib19","doi-asserted-by":"crossref","first-page":"232504","DOI":"10.1103\/PhysRevLett.113.232504","article-title":"Exclusive J\/psi photoproduction off protons in ultraperipheral p-Pb collisions at \u221a(s(NN))\u00a0= 5.02 TeV","volume":"113","author":"Abelev","year":"2014","journal-title":"Phys Rev Lett"},{"key":"10.1016\/j.ekir.2022.02.023_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1152\/ajplegacy.1958.194.2.221","article-title":"Renal regulation of urea excretion in sheep","volume":"194","author":"Schmidt-Nielsen","year":"1958","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2022.02.023_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1152\/ajplegacy.1970.218.5.1363","article-title":"Contribution of urea to urinary concentrating ability in the dog","volume":"218","author":"Schmidt-Nielsen","year":"1970","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ekir.2022.02.023_bib22","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1172\/JCI88532","article-title":"High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation","volume":"127","author":"Kitada","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.02.023_bib23","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1172\/JCI88530","article-title":"Increased salt consumption induces body water conservation and decreases fluid intake","volume":"127","author":"Rakova","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.02.023_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2022.02.023_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2022.02.023_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ki.2013.453","article-title":"Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation","volume":"85","author":"Matsusaka","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.02.023_bib27","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1681\/ASN.2012010078","article-title":"Multiphoton imaging of the glomerular permeability of angiotensinogen","volume":"23","author":"Nakano","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.02.023_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2169\/internalmedicine.3624-19","volume":"59","author":"Ohashi","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2022.02.023_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.HYP.0000050102.90932.CF","article-title":"Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension","volume":"41","author":"Kobori","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.02.023_bib30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/HYPERTENSIONAHA.108.123802","article-title":"Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients","volume":"53","author":"Kobori","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2022.02.023_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.02.023_bib32","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.02.023_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ekir.2022.02.023_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2022.02.023_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.02.023_bib36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.02.023_bib37","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.02.023_bib38","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922012037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922012037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:40:06Z","timestamp":1762832406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922012037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2468024922012037"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.02.023","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With\u00a0Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}